International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 1 Jan - Feb 2025, pp: 448-451 www.ijprajournal.com ISSN: 2456-4494

# Overview of the Common Technical Documents

Sakshi R. Hase*, Roshani G. Zaware*,Akash K. Shelke,
*(M.pharm Quality Assurance)*
*Shri Swami Samarth Institute of Pharmacy Malwadi,Bota.*

Date of Submission: 10-01-2025 Date of Acceptance: 20-01-2025

**ABSTRACT:**
"This article addresses the information needed to compile dossiers for different countries and the CTD format, which is anticipated to drastically cut down on the time and resources needed by the industry to create reports and applications for worldwide registration. The Common Technical Document (CTD) was created to provide a standard format for technical documentation submitted with an application for the registration of a pharmaceutical product for human use across Europe, the United States, and various Asian countries. The CTD dossier consists of five primary modules: Prescription and administrative information is covered in Module 1; overviews and summaries of Modules 3–5 arecovered in Module 2; pharmaceutical documentation quality is covered in Module 3; non-clinical reports (pharmacology/toxicology) are covered in Module 4; and clinical study reports (clinical trials) are covered in Module 5. Each module's content is described in detail in the guidelines, and most submissions now need to use the CTD format for submission dossiers. These documents are used to assess the effectiveness of a customized drug regimen, making these details critical. They help in determining, formulating, assessing, and evaluating medication-related issues, patient-described symptoms, and conditions that the patient self-diagnoses.

**Keywords**:Common Technical Document,Dossier.

## I. INTRODUCTION

Before the Common Technical Document (CTD) was implemented in 2002, the European Union (EU), the United States (USA), and Japan each had their own regulatory systems and formats for submitting drug approval dossiers. The FDA had guidelines for New Drug Applications (NDAs), Europe required expert reports and summaries, and Japan required a GAIYO summary. The CTD, standardized by the FDA in 2000, consolidated these formats into a unified structure for clinical, non-clinical, manufacturing, and technical data across all three regions. By July 2003, the CTD was adopted as the preferred format for NDAs in the USA and became mandatory in Europe and Japan, with other countries like Canada and Switzerland also adopting it. The CTD consists of five modules: Module 1 (administrative data), Module 2 (summaries of other modules), Module 3 (quality information), Module 4 (non-clinical study reports), and Module 5 (clinical study reports). The ICH M4 guidelines provide instructions for document placement and pagination, along with a list of frequently asked questions.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 1 Jan - Feb 2025, pp: 448-451 www.ijprajournal.com ISSN: 2456-4494




**Here's a summary of the provided content:**
**Module 1**: Contains administrative and regional data not part of the CTD (Common Technical Document). This includes geographical information, legal documents, application forms, and suggested labels.

**Module 2:** Provides an outline and summaries for Modules 3-5. It includes:
- A brief introduction to the medication (pharmacological class, mechanism of action, and clinical use).
- Overviews of non-clinical and clinical practices.
- Summaries of non-clinical and clinical data, presented in written and tabulated forms.

**Module3:** Contains information related to the quality of the drug, including chemistry, manufacturing, and controls (CMC) details. This section follows the ICH guidelines and includes information on drug substances, pharmaceutical products, and references to literature.

**Module 4:** Focuses on non-clinical study reports, including pharmacology, pharmacokinetics, and toxicology. It also includes comprehensive summaries of the studies and data, with a detailed

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 1 Jan - Feb 2025, pp: 448-451 www.ijprajournal.com ISSN: 2456-4494

analysis in the non-clinical written summaries (100-150 pages).

**Module 5:** Covers clinical study reports, including summaries and detailed reports on biopharmaceutical studies, pharmacokinetics, pharmacodynamics, safety, efficacy, and post-marketing experience. It includes tabular summaries of clinical studies, individual patient case reports, and references to relevant literature.

Each module is structured to provide specific information about the medication, from administrative details to in-depth clinical and non-clinical data.

- **Kinds of entries required for CTD**

CTD is compulsory for a wide range of entries as examined below:
1. Production and marketing of new drugs that have been approved (new chemical entities and indications, new dosage forms, and new routes of administration, among other things), as a wrapped up drug item, for first time finish with analyst and for resulting applications until 4 years.
2. Developed and modified release formulations (even after being approved by CDSCO for four years).
3. Drugs that fall under the heading "fixed dose combinations" in Appendix VI of Schedule Y of the Drugs and Cosmetics Act and Rules of 1945.

- **ICH's goal is to prepare CTD:**

1. The curve of ICH is disregarded todepictive testing of creature and human and to arrive at a typical comprehension of the specialized necessities to help the enlistment process in the three ICH areas.
2. Harmonized guidelines enable these goals to be accomplished, resulting in a more efficient use of human, animal, and material resources, the elimination of unnecessary delays in the comprehensive application and proposal of new medicines, as well as the preservation of high-quality efficacy and safety and regulatory obligations to safeguard public health.
3. The ICH hopes to achieve many of its goals with the creation of the Common Technical Document (CTD).
Any rule which is given by ICH passesthrough various advances.

- **The importance of the CMC (chemistry,manufacturing, and controls) section in the CTD dossier:**

The CMC (chemistry, manufacturing, and controls) section is crucial and comprehensive for any clinical trial or marketing application.
1. In the event that the assembling system can't be shownto its greatest norm and don't fulfilled the controllers need as well asitem have not their quality norm as referenced in Pharmacopeia than it very well may be opportunity to medication may lost the advertisingendorsement.
2. So it is essential to show the standard quality cycle and boundary of medication producing subtleties and other boundary cover in module 3 Quality contain Science, assembling and Control.
3. The science, fabricating and controls(CMC) segment is a vital piece of any clinical preliminary or showcasing application.
If the product's quality and manufacturing process cannot be demonstrated to meet regulators' expectations, drugs may not receive marketing approval.
4. The ICH rule Q1A(R2) (Solidness Testing of New Medication Substances and Items) characterizes the strength information bundle required for new drugsubstances and items submitted for endorsement in every one of the significant districts that acknowledge the ICHguidelines (i.e., US, Japan and EU).

- **Obstacles of CTD (c67)**

1. CTD is just an organization and it's anything but a single dossier with a solitary substance.
2. Lawful prerequisites different in the different areas.
3. All requirements have not yet been harmonised by the ICH guidelines.
4. Pharmacopeia's are not orchestrated.
5. Candidate might have provincial inclinations.
6. The eCTD has proven to be essential and comprehensive in boosting application submission efficiency and reviewer productivity.

**Advantages:**
1. Simplifies the application review process and avoids delays by ensuring essential information is included.
2. Reduces time and resources needed for human drug registration applications and streamlines electronic submission processes.
3. Standardized documentation facilitates regulatory reviews and communication with applicants.
4. Saves time and resources.
5. Enhances the efficiency of regulatory reviews and communication.
6. Ensures proper data organization.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 1 Jan - Feb 2025, pp: 448-451 www.ijprajournal.com ISSN: 2456-4494

**Hidden Benefits by CTD:**

1. Promotes global application harmonization.
2. Establishes standards for document preparation during the IND stages.
3. Simplifies data and project management through standardization.
4. Leads to more predictable reviews.
5. Streamlines application analysis.
6. Eases data exchange.
7. Facilitates electronic submissions and reports.

## II. CONCLUSION:

An excellent dossier is necessary for any export market and can be produced through an accurate Formulation Development process. Proper planning and implementation of Formulation development will facilitate the creation of superior dossiers and the ability to address inquiries from regulatory bodies. Pharmaceutical product registration in any of the exporting nations requires the assembly of documentation in a format that is globally acceptable for both regulated and unregulated markets. The CTD and eCTD formats were created in response to notable differences in the specifications for pharmaceutical product dossier registration.

## REFERENCES:

[1]. Of Module 2 and Module 3: Quality (R1) [cited 2002 Sep 12]. Available from: http://www.ich.org/filead min/Public_Web_Site/ICH_Products/CTD /M4_R1_ Quality/M4Q__Jordan D. An overview of the Common Technical Document (CTD) regulatory dossier. Med Writ. 2014;23(2):101-105.

[2]. Patel DH, Badjatya JK, Patel AA. Preparation and Reviewof Chemistry, Manufacturing and Control (CMC) sectionsof CTD Dossier for Marketing Authorization. InternationalJournal of Drug Regulatory Affairs. 2017;5(2):1-12.

[3]. Mahaparale, S., and Desai, B. (2018) 'Role and Overview of Drug Regulatory Affairs in the Pharmaceutical Industry with Implementation of CTD and eCTD.' World Journal of Pharmaceutical Research. [Internet], 201-215. Available from: www.wjpr.net. [21 March 2018].

[4]. Janjal, V. (2021) 'Recent Drug Regulatory Affairs and CTD Module Progress Review for Submission of Pharmaceutical Products.' GSC Biological and Pharmaceutical Sciences. [Internet], 16 200-221. Available from: https.//doi.org|10.30574| gscbps. 2021.16.3.0279. [26 September 2021].

[5]. 10.Bhalodiya H. A.*, Boda J. M., Shah J. S., Patel P. B., Vaghela J. P. The Common Technical Document (CTD): Taking Indian NDA process towards Globalization. International Journal of Pharmaceutical Sciences Review and Research (IJPSRR). July–Aug: 2011; 9(2): 181-187.

[6]. ICH M4 Guideline: Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use (R3) [cited 2004 Jan 13]. Available from:http://www.ich.org/fileadmin/Public _Web_Site/ICH_Products/CTD/M4_R3_ Orga nisation/M4_R3__organisation.pdf.

[7]. ICH M4 Guideline: General Questions & Answers Document (R3) [2004 June ]

[8]. Sahitya, K. et al. (2020) 'Regulatory Pathway for Registration and Approval of Indian Drug Products in Overseas Market.' Journal of Pharmaceutical Science and Research. [Internet], 12 (0975-1459), 1150- 1161. Available from: www. Just. Pharma info. In.

[9]. Chowdary, K., and Ravi Shankar, K. (2015) 'CTD - A Critical Document for Dossier Submission: An Overview.' World Journal of Pharmacy and Pharmaceutical Science.

[10]. ICH M4Q Guideline: Quality Overall Summary R1_.pdf.